Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leyland-Jones, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leyland-Jones, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:993-994, 2002
© 2002 European Society for Medical Oncology

Editorial

Trastuzumab therapy for the metastatic patient: does the primary match?

B. Leyland-Jones

McGill University, Department of Oncology, Montreal, Canada (E-mail: leyland@med.mcgill.ca)

The first 10% of the full text of this article appears below.

"They were a well-matched couple as both of them were madly in love—she with herself, and he with himself."

This issue of Annals of Oncology contains a critically important article [1] comparing HER-2 status between primary breast cancer and corresponding distant metastatic sites. Since trastuzumab is indicated for HER-2-overexpressing breast cancer patients with metastatic disease, and since one relies almost exclusively on pathological testing in the primary breast sample, the perfect matching of primary with metastatic HER-2 testing becomes crucial. The seminal work of Fidler, Folkman (and others referenced in the Gancberg article) have not only demonstrated critical biological differences between primary and metastatic tumours, but used these differences as the basis for novel antimetastatic approaches to therapy. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Kretz-Rommel, F. Qin, N. Dakappagari, R. Cofiell, S. J. Faas, and K. S. Bowdish
Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
J. Immunol., January 15, 2008; 180(2): 699 - 705.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro, and E S Lee
Serum HER-2 concentration in patients with primary breast cancer
J. Clin. Pathol., April 1, 2006; 59(4): 373 - 736.
[Abstract] [Full Text] [PDF]